心臓弁膜器の世界市場-2023年～2030年

概要

心臓弁膜器は、弁形成術や弁置換術などの医療処置の際に心臓弁を切開するために使用される手術器具です。

弁膜切開術は、弁狭窄や逆流を緩和するために弁輪切開器を使用する外科手術です。これは、影響を受けた弁尖に制御された切開創を形成することによって行われます。これらの切開は狭窄した弁を広げ、その機能を改善し、心臓内の適切な血流を回復するのに役立ちます。心臓外科医は、弁関連疾患を治療し、心臓機能と患者の健康を改善するために弁膜器を使用します。

市場促進要因：市場抑制要因

大動脈弁狭窄症の有病率の増加が市場成長の原動力となる見込み

大動脈弁狭窄症は、大動脈弁が狭くなって心臓の左心室から全身への血液の流れを妨げる疾患です。大動脈弁狭窄症の重症例に対して外科的介入が必要な場合、弁輪切開術をバルブロトームを使って行うことができます。

この医療手技では、大動脈弁の厚い弁尖や癒合した弁尖に正確な切り込みを入れて弁口を広げます。これにより弁の柔軟性が向上し、心臓への圧力が軽減されるため、胸痛や息苦しさなどの症状が短期的に緩和されます。しかし、永久的な解決策にはならないかもしれないです。

さらに、欧州心臓病学会によると、大動脈弁狭窄症（AS）は、先天性異常のない65歳未満の人ではあまり一般的ではないが、その有病率は年齢とともに増加します。米国では2番目に多い弁膜症です。65歳では人口の約5％がASであり、その有病率は年齢とともに著しく増加します。

さらに最近の研究によると、人口の約12.4％がASであり、75歳以上では3.4％が重篤な症状を経験しています。ASの有病率は年齢とともに著しく増加し、50～59歳では0.2％、80～89歳では9.8％です。毎年1,000人に5人程度が新たにASに罹患し、一般的には60歳前後で発症します。

臨床的に重要なASを有する若年者は二尖大動脈弁疾患を有することが一般的である一方、三尖大動脈弁狭窄症は70歳以上でより一般的になり、しばしば大動脈弁置換術を必要とします。二尖大動脈弁は珍しいものではなく、人口の約0.5～0.8％にみられます。高所得国ではASの負担が増加しており、2050年までに治療を必要とする高齢患者（75歳以上の重症の症候性AS）が大幅に増加し、米国と欧州の両方で倍増すると予測されています。アイスランドでも、2040年までに70歳以上の重症ASの有病率が2倍になり、2060年までに3倍になると予想されています。

さらに、弁修復を含む心臓手術件数の増加や、心臓弁膜症の早期診断・治療の重要性に対する意識の高まりが、予測期間中の市場牽引要因として期待されています。

阻害要因：

心臓弁の手術や関連処置は高額であり、出血、感染、近隣構造物への損傷などの潜在的リスクがあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 大動脈弁狭窄症の有病率の増加
  • 抑制要因
    • バルブロトームに伴うリスク
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• パイプライン分析
• 特許分析
• DMIオピニオン

第6章 COVID-19分析

第7章 製品タイプ別

• 拡張型心臓弁膜器
• オーバーザワイヤー型心臓弁膜器

第8章 手術タイプ別

• 弁切開術
• 僧帽弁交連切開術
• 大動脈弁交連切開術
• 三尖弁交連切開術
• その他

第9章 エンドユーザー別

• 病院
• 外来手術センター
• 心臓外科センター
• 心臓カテーテル検査室
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• LeMaitre Vascular
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• B. Braun SE
• Andramed GmbH
• LimFlow, Inc.
• Teleflex Incorporated
• Symmetry Surgical Inc.

第13章 付録

Overview

A cardiac valvulotome is a surgical instrument used to cut or incise heart valves during medical procedures such as valvuloplasty and valve replacement surgeries.

Valvulotomy is a surgical procedure that uses a valvulotome to alleviate valve stenosis or regurgitation. This is done by creating controlled incisions in the affected valve leaflets. These incisions can widen narrowed valves and improve their functionality, which helps to restore proper blood flow within the heart. Cardiac surgeons use valvulotomes to treat valve-related diseases and improve cardiac function and patient well-being.

Market Dynamics: Drivers and Restraints

Increasing prevalence of aortic stenosis is expected to drive market growth

The use of a cardiac valvulotome can be beneficial in treating aortic stenosis, which is a condition that causes the aortic valve to narrow and impede the flow of blood from the heart's left ventricle to the rest of the body. When surgical intervention is necessary for severe cases of aortic stenosis, a valvulotomy procedure can be conducted using a valvulotome.

In this medical procedure, precise cuts are made in the thick or fused leaflets of the aortic valve to widen its opening. This improves the flexibility of the valve and reduces pressure on the heart, providing short-term relief from symptoms like chest pain and breathlessness. However, it may not be a permanent solution.

Moreover, the European Society of Cardiology states that Aortic stenosis (AS) is not very common in people under 65 years of age without a congenital abnormality, but its prevalence increases with age. In the United States, it is the second most common valvular lesion. At the age of 65, about 5% of the population has AS and its prevalence increases significantly with age.

In addition, according to recent studies, approximately 12.4% of the population has AS, with 3.4% experiencing severe symptoms among those aged 75 and older. The prevalence of AS increases significantly with age, ranging from 0.2% in the 50-59 age group to 9.8% in those aged 80-89 years. Around 5 in 1,000 individuals experience new cases of AS each year, and this typically occurs in people around the age of 60.

It is common for younger people with clinically significant AS to have bicuspid aortic valve disease, while tricuspid aortic valve stenosis becomes more prevalent in those over 70 years old, often requiring aortic valve replacement. Bicuspid aortic valves are not uncommon, occurring in approximately 0.5-0.8% of the population. In high-income countries, there is an increasing burden of AS, with a significant rise in elderly patients needing treatment (severe symptomatic AS aged 75 years and above) projected by 2050, doubling in both the USA and Europe. Iceland is also expected to have a doubling in the prevalence of severe AS among those aged ≥70 by 2040, with a tripling expected by 2060.

Furthermore, the rising number of cardiac surgeries, including valve repair, and increasing awareness of the importance of early diagnosis and treatment of heart valve conditions are the factors the market is expected to drive the market over the forecast period.

Restraint:

Cardiac valve surgeries and associated procedures are expensive, with potential risks of bleeding, infection, and damage to nearby structures, and the availability of alternatives are the factors expected to hamper the market over the forecast period.

Segment Analysis

The global cardiac valvulotome market is segmented based on product type, surgery type, end user, and region.

The Expandable Cardiac Valvulotome from the Product Type Segment Accounted for Approximately 37.6% of the Cardiac Valvulotome Market Share

Expandable cardiac valvulotomes are becoming more common in modern surgical practice. These devices offer flexibility and adjustability to surgeons and enable the controlled expansion or dilation of valve leaflets. They are precise and versatile, making them suitable for various valve-related procedures like valvuloplasty and valvulotomy. The expandable cardiac valvulotomes are particularly useful in treating valve stenosis and regurgitation.

Moreover, the increasing prevalence of valve diseases, the growing aging population, and advancements in cardiac surgery are the factors expected to drive the market over the forecast period.

For instance, advancements in cardiac surgery have led to the development of more sophisticated and precise instruments, such as Expandable Cardiac Valvulotomes. These tools play a crucial role in transcatheter aortic valve replacement (TAVR) procedures.

TAVR is a less intrusive method of treating aortic valve stenosis, which previously required open-heart surgery. This procedure involves using a catheter to deliver a collapsible artificial valve to the heart, typically through a small incision in the groin or chest.

Before the deployment of a new artificial valve, expandable cardiac valvulotomes are used to either predilate or enlarge the native aortic valve, guaranteeing a secure fit and optimal functionality. The use of instruments like expandable cardiac valvulotomes in TAVR, a minimally invasive procedure, minimizes patient trauma, shortens hospital stays, and speeds up recovery compared to traditional open-heart surgery. This innovation highlights how precise instruments are crucial in modern cardiac surgery, improving patient outcomes, and transforming treatment approaches for valvular heart diseases. Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Analysis

North America accounted for approximately 40.3% of the market share in 2022

North America is expected to hold the largest market share owing to the presence of key players, and the increasing prevalence of valvular heart disease.

For instance, according to data from the Centers for Disease Control and Prevention (CDC), Americans suffer from valvular heart disease, and this number tends to increase among older adults. Among the population, approximately 1 in 40 people experience significant valvular heart disease. The mitral and aortic valves are most commonly affected, with around 4 million Americans experiencing significant mitral valve regurgitation. Additionally, roughly 250,000 new cases are diagnosed each year.

The statistics show that many patients require treatment for valvular heart diseases, with the mitral and aortic valves being particularly affected. This widespread occurrence of heart conditions is likely to increase the need for cardiac valvulotomes and other surgical interventions, leading to growth in the cardiac valvulotome market as healthcare providers work to find effective solutions for this common health problem. Hence, owing to the above factors, the North America region is expected to hold the largest market share over the forecast period.

COVID-19 Impact Analysis:

The COVID-19 pandemic significantly impacted the cardiac valvulotome market by leading to a reduction in the number of cardiac surgeries and valvulotomy procedures performed. For instance, a study was conducted in Lithuania to assess how the COVID-19 pandemic affected a cardiac surgery center's operations. The study revealed that the pandemic had a considerable impact on adult cardiac surgery, resulting in a decline in surgical procedures and a rise in mortality rates. Despite the increased risk of complications in COVID-19-positive patients, the study found that carrying out planned cardiac surgeries with appropriate protective measures during quarantine was a better alternative than completely halting elective cardiac surgeries.

Furthermore, the primary causes of this decrease were the reallocation of healthcare resources to address the surge in COVID-19 cases, the prioritization of critical care, and many patients' reluctance to seek medical attention for non-emergency conditions due to infection concerns. As a result, demand for valvulotomy procedures dropped temporarily, affecting the market. However, as healthcare systems gradually adjusted and resumed elective procedures, the market began to recover, highlighting the resilience of cardiac valvulotome procedures as necessary treatments for valvular heart diseases.

Competitive Landscape

The major global players in the cardiac valvulotome market include: LeMaitre Vascular, B. Braun SE, Andramed GmbH, LimFlow, Inc., Teleflex Incorporated, and Symmetry Surgical Inc. among others.

Why Purchase the Report?

• To visualize the global cardiac valvulotome market segmentation based on product type, surgery type, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of cardiac valvulotome market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global cardiac valvulotome market report would provide approximately 49 tables, 57 figures, and 170 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Surgery Type
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing prevalence of aortic stenosis
  • 4.1.2. Restraints
    • 4.1.2.1. Risk associated with valvulotome
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Pipeline Analysis
• 5.6. Patent Analysis
• 5.7. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Product Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.1.2. Market Attractiveness Index, By Product Type
• 7.2. Expandable Cardiac Valvulotome*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Over the Wire Cardiac Valvulotome

8. By Surgery Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
  • 8.1.2. Market Attractiveness Index, By Surgery Type
• 8.2. Valvulotomy*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Mitral Valve Commissurotomy
• 8.4. Aortic Valve Commissurotomy
• 8.5. Tricuspid Valve Commissurotomy
• 8.6. Others

9. By End User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.1.2. Market Attractiveness Index, By End User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Ambulatory Surgical Center
• 9.4. Cardiac Surgery Centers
• 9.5. Cardiac Catheterization Labs
• 9.6. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Spain
    • 10.3.6.5. Italy
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Surgery Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. LeMaitre Vascular*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. B. Braun SE
• 12.3. Andramed GmbH
• 12.4. LimFlow, Inc.
• 12.5. Teleflex Incorporated
• 12.6. Symmetry Surgical Inc.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us